VAM
IOVA icon

Visium Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

Visium Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-30,900
Closed -$178K – 714
2015
Q3 		$178K Sell
30,900
-1,100
-3% -$8.57K ﹤0.01% 818
2015
Q2 		$293K Buy
+32,000
New +$357K ﹤0.01% 823

Other funds holding IOVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Visium Asset Management's IOVA Position: Q4 2015 in Review

Visium Asset Management sold out of Iovance Biotherapeutics (IOVA) in Q4 2015, closing a stake of 30,900 shares — an estimated $178K sold.

Visium Asset Management first reported a position in IOVA in Q2 2015 and held it in 2 quarters. The position peaked at $293K in Q2 2015. 82 funds tracked by Wall St. Rank hold IOVA as of Q4 2015.

  • Visium Asset Management reported no remaining Iovance Biotherapeutics position as of Q4 2015 after selling out during the quarter.
  • Visium Asset Management sold 30,900 Iovance Biotherapeutics shares in Q4 2015, an estimated $178K.
  • Visium Asset Management first reported a position in Iovance Biotherapeutics in Q2 2015 and held it in 2 quarters.
  • Visium Asset Management's Iovance Biotherapeutics position peaked at $293K in Q2 2015.
  • 82 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2015.

Based on Visium Asset Management's 13F filing for Q4 2015, filed 12 Feb 2016.